Expression Of PCNA And NDRG1in Prostate Cancer And Benign Prostatic Hyperplasia And Their Significance

Objective:To investigate the expression and significance_of two biological tumor markers, PCNA and NDRG1, in prostate cancer and benign prostatic hyperplasia, evaluate the reliabilities of diagnosis based on their expression in the course of cancer occurrence and development, and explore the influence of combined measurement of the two markers on diagnosis of prostate cancer.Method:We collected data from78patients who were hospitalized in the Yanbian University hospital from2007to2012due to prostate cancer or benign prostatic hyperplasia. Among them there were67prostate cancer patients, and we divided them into two groups:poorly differentiated group of49with pathological Gleason score, and highly differentiated group of18with pathological Gleason score. Those11patients with benign prostatic hyperplasia served as control group. According to oncology TNM staging of prostate cancer can be divided into stage T1, T2, T3, T4,among them T1and T2are divided into a set of groups, and a group T3and T4, respectively, to compare between the two groups, according to the presence of bone metastases, prostate cancer is divided into the two groups respectively, comparison between the two groups. All the data were analyzed using chemical method of immunehistochemistry.Results:1. The positive of PCNA in prostate cancer and in benign prostatic hyperplasia is statistically meaningful (P<0.05). The positive of PCNA in poorly differentiated group and in highly differentiated group is as well statistically meaningful (P<0.05); In the oncology TNM staging, T1and T2stage total expression rate and the total T3and T4expression rate show divergence, which is statistically meaningful (P<0.05); PCNA is significant differences between in prostate cancer of bone metastasis tissues, with of no bone metastasis tissues, which is statistically meaningful (P<0.05).2. The positive of NDRG1expression in prostate cancer and in benign prostatic hyperplasia show divergence, statistically meaningful (P<0.05). The positive of NDRG1in poorly differentiated group and in highly differentiated group show no difference, and this is not statistically meaningful (P>0.05);In the oncology TNM staging, NDRG1In T1and T2stage total expression rate and the total T3and T4expression rate is no difference, which is statistically meaningless (P>0.05); PCNA in prostate cancer with bone metastasis tissues and without bone metastasis tissues both express no difference, statistically meaningless (P>0.05).3. The PCNA and NDRG1expressed in prostate cancer and benign prostatic hyperplasia negatively correlated, with statistically meaningless (P<0.05, r=0.998).Conclusion:1. The expression level of PCNA in prostate cancer is remarkably higher than that in benign prostatic hyperplasia. It is closely related to the occurrence and development of prostate cancer and pathological Gleason score, TNM staging and the presence of bone metastases of prostate cancer, indicating that PCNA is an important biological tumor marker in diagnosis of prostate cancer, its positivity represents tumor proliferation activity and malignant degree and prognosis of prostate cancer..2. NDRG1is over expressed in both prostate cancer tissue and benign prostatic hyperplasia tissue, and its level of expression in benign prostatic hyperplasia tissue is higher than that in prostate cancer tissue, closely related to pathological Gleason score. This indicates NDRGl’s potential for a new biological tumor marker in diagnosis of prostate cancer. But for TNM staging and the presence of bone metastasis of prostate cancer NDRG1express no difference3. Both PCNA and NDRG1have high specificity and sensitivity in the process of prostate cancer occurrence and development Combined test of PCNA and NDRG1can effectively improve prostate cancer diagnosis.